P - Caution when used during pregnancy
Salmeterol is a long-acting beta2-adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is currently available as a metered-dose inhaler (MDI) or a proprietary "disk-styled" inhaler that releases a powdered form of the drug.
Salmeterol is a direct-acting sympathomimetic which relaxes bronchial smooth muscle by its selective action on β2 receptors with little effect on heart rate.
Onset
Oral inhalation: 10-20 minutes.
Duration
12 hours.
Absorption
Plasma concentrations are negligible after inhalation.
Distribution
About 96% bound to plasma proteins.
Metabolism
Hepatically hydroxylated.
Excretion
About 25% and 60% of the dose was eliminated in the urine and faeces respectively, over a period of 7 days.
Information Not Available
Fine skeletal muscle tremor especially hands, tachycardia, palpitations, muscle cramps, headache, paradoxical bronchospasm, angioedema, urticaria, hypotension and collapse.
Warnings
When added to usual asthma therapy, there may be an increase in asthma-related deaths. Only use salmeterol as additional therapy for patient not adequately controlled on other asthma-controller medications (eg, low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with 2 maintenance therapies, including salmeterol.
Monitor
Monitor for signs of worsening asthma.
Overdosage
May result in exaggeration of adverse effects e.g. tachycardia and arrhythmia.
Pregnancy. Arrhythmias, hyperthyroidism, hypertension, DM, myocardial insufficiency, susceptibility to QT-interval prolongation. May cause paradoxical bronchospasm. Not to be used for treatment of acute bronchospasm or patients with deteriorating asthma. Monitor serum potassium concentrations in severe asthma.
Diuretics, corticosteroids and xanthines may augment hypokalaemia. Risk of severe hypertension when used with MAOIs, TCAs and other sympathomimetics. Increased susceptibility to cardiac arrhythmias caused by digoxin and other cardiac glycosides.
Information Not Available
Inhalation
Chronic asthma, Chronic obstructive pulmonary disease
Adult: As metered-dose aerosol: 2 inhalations of 25 mcg bid up to 100 mcg bid. As dry powder inhalation: 50 mcg bid or 100 mcg bid if necessary.
Child: As metered-dose aerosol: ≥4 yr: 50 mcg bid.
Information Not Available
Caution when used during pregnancy.
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus.
Information Not Available
Information Not Available
Information Not Available
Information Not Available
Inhalation
Store at 20-25°C.
Inhalation
Store at 20-25°C.
You will hear from us only if the bid amount matches the minimum threshold and intended usage match our vision. You can resubmit another bid.